{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Changed Section Planned Sensitivity and Subgroup Analysis to 8.1.8 and', 'delete the first, third and last sentence of the section.', 'Rationale: Align with updated analysis plan as outlined above.', 'Changed Section Pharmacokinetic and Exposure-Response Analyses to 8.1.9.', 'Modified Synopsis Section 1.2 Criteria for Evaluation, Pharmacokinetic,', 'Section 5.3.5 Pharmacokinetic Variables and Section 8.1.9 Pharmacokinetic', \"and Exposure-Response Analyses to change 'plasma' to 'serum.'\", 'Rationale: To update numbering in the section of the protocol and align with', 'the lab manual.', 'Modified Section 8.3 Type I Error Adjustment Procedure for Multiple Testing', 'to', 'include the DLL3 high set, update the null hypotheses and level of', 'significance. Figure 3 was also added. This is outlined above in the Synopsis', 'section.', 'Rationale: Align with updated analysis plan as outlined above.', 'Modified Section 10.1 Source Documents to clarify that the Investigator', 'Awareness date of a SAE should be noted in the source, not the EDC.', 'Rationale: This data point cannot be captured in the EDC.', \"Added the following addition to References, '19. AbbVie. Rovalpituzumab\", 'Tesirine Dear Rova-T Investigator Letter. 05 December 2018.', 'Rationale: Added reference due to new safety data.', 'Modified Appendix B: List of Protocol Signatories', 'Rationale: Updated new team members since last amendment.', 'Modified Appendix C: Echocardiogram. Now a required assessment listed', 'under Screening.', 'Rationale: To provide a bigger window for sites to complete the assessment.', \"Modified Footnote b under Appendix C to say, 'End of Treatment Visit\", 'procedures should be done within 7 days of documentation of the decision to', 'discontinue treatment and prior to subjects beginning any new anti-cancer', \"therapy if possible.'\", 'Rationale: Updated to be consistent with EOT treatment language.', '8']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Modified Footnote e under Appendix C to add the following language,', \"'Cycle 1 Day 1 procedures, with the exception of weight.'\", 'Rationale: Updated to clarify when weight should be done to be used for', 'dosing decisions.', 'Modified Footnote n under Appendix C to clarify when Echocardiograms are', 'required throughout the study and in relation to pericardial effusion', 'assessments.', 'Rationale: To allow for a larger window for the assessment to be completed.', 'Modified Footnote q under Appendix C to advise sites on the need to contact', 'TA MD for the gaps in tumor assessments.', 'Rationale: Updated to indicate when the TA MD should be consulted.', 'Make administrative changes of typographical errors, minor language and', 'word revision as needed throughout the document.', 'Rationale: Clarifies and ensures consistency throughout.', 'An itemized list of all changes made to this protocol under this amendment can be found', 'in Appendix K.', '9']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '1.2', 'Synopsis', 'AbbVie Inc.', 'Protocol Number: M16-298', 'Name of Study Drug: rovalpituzumab tesirine', 'Phase of Development: 3', '(Rova-T)', 'Name of Active Ingredient: rovalpituzumab', 'Date of Protocol Synopsis: 05 March 2019', 'tesirine', 'Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab', 'Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with', 'Extensive Stage Small Cell Lung Cancer (MERU)', 'Objectives:', 'Primary', 'To evaluate if rovalpituzumab tesirine improves progression-free survival, assessed by a Central', 'Radiographic Assessment Committee (CRAC) according to RECIST v1.1. and overall survival', 'in subjects with extensive-stage small cell lung cancer (ED SCLC) tumors with a high level of', 'DLL3 expression (DLL3high) who have ongoing clinical benefit (SD, PR, or CR) following', 'first-line platinum-based chemotherapy (cisplatin or carboplatin plus irinotecan or etoposide)', 'compared to placebo.', 'Secondary', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by CRAC and overall', 'survival in all randomized subjects compared to placebo.', 'To assess change in patient reported outcomes (PRO) with physical functioning as measured by', 'the EORTC QLQ-C30 questionnaire in all randomized subjects compared to placebo.', 'Exploratory', 'To evaluate rovalpituzumab tesirine anti-tumor activity by determining objective response rate', '(ORR), clinical benefit rate (CBR), and duration of responses (DOR) by CRAC and Investigator', 'assessment in DLL3hig and in all randomized subjects.', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by Investigator', 'assessment compared to placebo in DLL3high and in all randomized subjects.', 'To assess change from baseline in all patient reported outcomes (PRO) domains (except physical', 'functioning) measured by EORTC QLQ-C30/LC13 and EQ-5D-5L.', 'To characterize the pharmacokinetics and incidence of anti-therapeutic antibodies (ATAs)', 'against rovalpituzumab tesirine.', 'To evaluate pharmacodynamic and predictive biomarkers in blood and tumor for association', 'with sensitivity, efficacy and safety.', 'To explore DLL3 expression in circulating tumor cells (CTCs) for association with efficacy.', 'Investigators: Multicenter, International', 'Study Sites: Approximately 300', 'Study Population: Subjects with extensive-stage Small Cell Lung Cancer (ED SCLC) with ongoing', 'clinical benefit (SD, PR, or CR per RECIST v1.1) following completion of 4 cycles of first-line', 'platinum-based chemotherapy (cisplatin or carboplatin in combination with etoposide or irinotecan).', '10']\n\n###\n\n", "completion": "END"}